| Literature DB >> 35168246 |
Wooseob Kim1, Julian Q Zhou1, Stephen C Horvath1, Aaron J Schmitz1, Alexandria J Sturtz1, Tingting Lei1, Zhuoming Liu2, Elizaveta Kalaidina3, Mahima Thapa1, Wafaa B Alsoussi1, Alem Haile4, Michael K Klebert4, Teresa Suessen5, Luis Parra-Rodriguez6, Philip A Mudd7,8, Sean P J Whelan2, William D Middleton5, Sharlene A Teefey5, Iskra Pusic9, Jane A O'Halloran6, Rachel M Presti6,8, Jackson S Turner1, Ali H Ellebedy10,11,12.
Abstract
Germinal centres (GC) are lymphoid structures in which B cells acquire affinity-enhancing somatic hypermutations (SHM), with surviving clones differentiating into memory B cells (MBCs) and long-lived bone marrow plasma cells1-5 (BMPCs). SARS-CoV-2 mRNA vaccination induces a persistent GC response that lasts for at least six months in humans6-8. The fate of responding GC B cells as well as the functional consequences of such persistence remain unknown. Here, we detected SARS-CoV-2 spike protein-specific MBCs in 42 individuals who had received two doses of the SARS-CoV-2 mRNA vaccine BNT162b2 six month earlier. Spike-specific IgG-secreting BMPCs were detected in 9 out of 11 participants. Using a combined approach of sequencing the B cell receptors of responding blood plasmablasts and MBCs, lymph node GC B cells and plasma cells and BMPCs from eight individuals and expression of the corresponding monoclonal antibodies, we tracked the evolution of 1,540 spike-specific B cell clones. On average, early blood spike-specific plasmablasts exhibited the lowest SHM frequencies. By contrast, SHM frequencies of spike-specific GC B cells increased by 3.5-fold within six months after vaccination. Spike-specific MBCs and BMPCs accumulated high levels of SHM, which corresponded with enhanced anti-spike antibody avidity in blood and enhanced affinity as well as neutralization capacity of BMPC-derived monoclonal antibodies. We report how the notable persistence of the GC reaction induced by SARS-CoV-2 mRNA vaccination in humans culminates in affinity-matured long-term antibody responses that potently neutralize the virus.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35168246 PMCID: PMC9204750 DOI: 10.1038/s41586-022-04527-1
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 69.504